2.
患者治疗特点与PFS之间的关系
Relationship between PFS and therapeutic characteristics
| n | Rate (%) | Median PFS (month) | P | |
| ◎：Sixty-two patients had received chemotherapy before gefitinib treatment, including neo-adjuvant chemotherapy, adjuvant chemotherapy and salvage chemotherapy. | ||||
| Treatment strategy | 0.540 | |||
| 1st line | 24 | 30.00 | 15 | |
| ≥2nd line | 56 | 70.00 | 13 | |
| Previous chemotherapy◎ | 0.082 | |||
| > 4 cycles | 30 | 48.39 | 16 | |
| ≤4 cycles | 32 | 51.61 | 12 | |
| Previous chemotherapy PFS◎ | 0.252 | |||
| > 6 months | 32 | 51.61 | 14 | |
| ≤6 months | 30 | 48.39 | 12 | |
| Skin rash | 0.171 | |||
| No | 50 | 62.50 | 13 | |
| Yes | 30 | 37.50 | 16 | |
| Grade 0-1 rash | 57 | 71.25 | 11 | 0.085 |
| Grade 2-4 rash | 23 | 28.75 | 19 | |
| Grade 0-1 diarrhea | 69 | 86.25 | 12 | 0.861 |
| Grade 2-4 diarrhea | 11 | 13.75 | 19 | |